Colorectal Disorders

Secretagogues Compared in Irritable Bowel Syndrome With Constipation

By August 29, 2018

While several secretagogues have been recently approved by the Food and Drug Administration (FDA), a lack of head-to-head trials led researchers to conduct a systematic review to compare the effectiveness of these agents in patients with IBS-C.

Anti-MAP Therapy Beneficial in Phase 3 Crohn's Disease Trial

By August 01, 2018

The randomized, double-blind, placebo-controlled study (N=331) achieved its primary endpoint and key secondary endpoints in the intent-to-treat (ITT) population.

Iron Therapies Compared in Patients With GI-Related Iron Deficiency Anemia

By July 30, 2018

The analysis also showed that the more severe the anemia was at baseline, the greater the response was to treatment with regard to hemoglobin changes.

Vedolizumab SC Induces Clinical Remission in Phase 3 Ulcerative Colitis Study

By July 23, 2018

The study included 384 adult patients with moderately to severely active UC who had an inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or tumor necrosis factor-alpha (TNFα)-antagonist therapy prior to being enrolled.

IV Acetaminophen Minimally Helpful for Colectomy Pain

July 09, 2018

More than 1 dose of intravenous acetaminophen on postoperative day 1 was associated with lower opioid utilization (−12.4%) vs non-use, while an even stronger reduction was seen in those receiving more than one oral acetaminophen dose (−22.6%).

Biologic Therapies Compared in Patients With Moderate-to-Severe Crohn's Disease

By June 20, 2018

For this study, researchers identified randomized controlled trials that included adults with moderate-to-severe CD treated with various biologic agents (i.e., infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab) as first- or second-line therapies compared with placebo or an active comparator.

Higher Vitamin D Levels Tied to Lower Risk of Colorectal Cancer

June 15, 2018

"Optimal 25(OH)D concentrations for colorectal cancer risk reduction, 75 to 100nmol/L, appear higher than current Institute of Medicine recommendations," the authors write.

Stelara Linked to Reduced Rates of Hospitalization, Surgery in Crohn's Disease

By June 04, 2018

The new analysis pooled patients from the UNITI-1 and UNITI-2 trials who had clinical response after a single intravenous (IV) dose of ustekinumab and entered a 5-year follow-up period.

FDA Approves New Treatment Option for Ulcerative Colitis

By May 30, 2018

The expanded FDA approval was based on results from two 8-week placebo-controlled induction trials and a 52-week maintenance study.

Ingestible Device Could Monitor Gastrointestinal Health

May 25, 2018

"IMBEDs enable new opportunities for gastrointestinal biomarker discovery and could transform the management and diagnosis of gastrointestinal disease," the authors write.

FDA Approves Hemospray to Treat Non-Variceal GI Bleeds

By May 09, 2018

The product is a single-use device that delivers hemostatic powder through the channel of an endoscope.

HBV Reactivation Examined in Patients Treated With TNF Antagonists

By May 03, 2018

The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.

FDA Grants Fast Track Status to IBS-D Treatment

By April 26, 2018

ORP-101 is a peripherally active partial agonist of the μ opioid receptor and antagonist of the κ opioid receptor.

Exposure to Anti-TNF Therapy Linked to Reduced Parkinson's Disease Risk

By April 24, 2018

Previous research has suggested a genetic and functional link between IBD and PD, however evidence regarding this association has been limited.

IBD and Anemia: Adverse Events After IV Iron Therapy Examined

By April 23, 2018

To examine the occurrence of adverse reactions in this patient population, researchers from John Hopkins University, Baltimore, Maryland, conducted a retrospective analysis of IBD patients who received IV iron infusions between 2010 and 2014 in the commercial claims database, MarketScan.

Opiate Use Linked to Early Mortality in IBD Patients

April 18, 2018

Heavy use in Crohn's, heavy or moderate use in ulcerative colitis tied to increased risk of death

<i>C. Difficile</i> Risk Higher With Stoma Reversal vs Difficile

April 18, 2018

Factors associated with C. difficile infection incidence in the 30-day postoperative period after controlling for other variables include stoma reversal (odds ratio, 2.701; P<.001), smoking (odds ratio, 1.520; P<.022), steroids (odds ratio, 1.677; P<.048), and disseminated cancer.

DPP-4 Inhibitors and Inflammatory Bowel Disease Risk: Is There a Link?

March 22, 2018

This first population-based study, found that DPP-4 inhibitors were associated with an increased risk of inflammatory bowel disease.

Xeljanz Gets FDA Committee Nod for Ulcerative Colitis Indication

By March 09, 2018

The GIDAC recommendations are provided to the FDA but they are not binding. The FDA has set a target PDUFA action date of June 2018.

Limited Data on Combination Biologic Therapy for IBD, Says Study

By February 28, 2018

The authors point out how, unlike other autoinflammatory conditions, "IBD has the benefit of effective and safe gut specific anti-integrin therapies which can provide a platform off of which combinations can be employed."

Modifiable Risk Factors ID'd in Recurring Acute Diverticulitis

February 23, 2018

"Knowledge of the rate and risk factors for recurrent acute diverticulitis is required to aid discussion and decision making with patients regarding the need and timing of elective surgery," the authors write.

Recurrent Salmonella enterica Typhimurium infection disables host protection against intestinal inflammation

February 04, 2018

Repeated gastrointestinal infections in mice, in this case Salmonella enterica Typhimurium (ST), caused intestinal tissue inflammation which escalated with repeated infections.

Firvanq Approved for <i>C. difficile</i>-Associated Diarrhea, <i>S. aureus</i> Colitis

By January 29, 2018

Firvanq oral solution will replace CutisPharma's FIRST-Vancomycin Unit-of-Use Compounding Kit, which was used by pharmacists to compound vancomycin oral liquid.

Trulance Gains New Indication for IBS With Constipation

By January 25, 2018

Apart from a single amino acid substitution, Trulance is structurally identical to human uroguanylin and is thought to replicate the pH-sensitive activity of uroguanylin.

Olmesartan Use Linked to Higher Rate of Enteropathy Compared to Other ARBs

By January 23, 2018

The authors note that while the evidence points to a higher rate of enteropathy outcomes in patients treated with olmesartan, the absolute rate was found to be low.

Reduced Stoma-Related Care Costs With Ceramide-Infused Ostomy Skin Barrier

January 16, 2018

The researchers found that over a 12-week period there was a significant reduction in stoma-related cost of care with use of the ceramide-infused barrier, resulting in a 14% relative decrease in cost.

Treating a Common Extraintestinal Manifestation of Inflammatory Bowel Disease

January 05, 2018

Mr. C, a 30-year-old male with Crohn's disease, presented to his clinician with symptoms of fatigue, lethargy, headaches, pallor, hair loss, irritability, and weakness.

Treatment Response Predictors ID'd for Infliximab Salvage in Severe UC

January 03, 2018

Those treated with accelerated (AI) versus standard infliximab induction strategies had a numerically higher colectomy rate; however, AI treatment was correlated with more severe biochemical disease.

Biosimilar Ixifi Gets FDA Approval for All Remicade Indications

By December 14, 2017

Ixifi is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor.

Sanofi Discontinues <i>C. Difficile</i> Tx Development

By December 08, 2017

Data that has been collected from the trial so far will be analyzed and shared with the scientific community in due time.